Literature DB >> 15698792

Synthesis, structure-activity relationship, and p210(bcr-abl) protein tyrosine kinase activity of novel AG 957 analogs.

Gurmeet Kaur1, Ven L Narayanan, Prabhakar A Risbood, Melinda G Hollingshead, Sherman F Stinson, Ravi K Varma, Edward A Sausville.   

Abstract

A series of novel, sterically hindered lipophilic analogs of AG 957 was designed and synthesized as potential protein tyrosine kinase (PTK) inhibitors. The in vitro activity, in vivo anti-leukemia activity, and pharmacology of these PTK inhibitors were studied. Some aspects of the structure-activity relationship associated with the carboxylic acid, phenol ring, and linker modifications are discussed. We have demonstrated that the 1,4-hydroquinone moiety is essential for activity and that sterically hindered esters contribute to enhanced in vivo efficacy. Adaphostin (NSC 680410) has emerged as the improved compound with the maximum in vivo anti-leukemia hollow fiber activity, concordant with the original lead compound AG 957. Currently, adaphostin is undergoing preclinical toxicology studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15698792     DOI: 10.1016/j.bmc.2004.12.003

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

1.  Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.

Authors:  Joya Chandra; Jeannette Tracy; David Loegering; Karen Flatten; Srdan Verstovsek; Miloslav Beran; Mercedes Gorre; Zeev Estrov; Nicholas Donato; Moshe Talpaz; Charles Sawyers; Kapil Bhalla; Judith Karp; Edward Sausville; Scott H Kaufmann
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

Review 2.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

3.  High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1.

Authors:  Dana Ungermannova; Junglim Lee; Gan Zhang; H Garry Dallmann; Charles S McHenry; Xuedong Liu
Journal:  J Biomol Screen       Date:  2013-04-15

Review 4.  Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies.

Authors:  Joya Chandra
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

5.  Synthesis of a novel adamantyl nitroxide derivative with potent anti-hepatoma activity in vitro and in vivo.

Authors:  Jin Sun; Shan Wang; Wei Bu; Meng-Ying Wei; Wei-Wei Li; Min-Na Yao; Zhong-Ying Ma; Cheng-Tao Lu; Hui-Hui Li; Na-Ping Hu; En-Hu Zhang; Guo-Dong Yang; Ai-Dong Wen; Xiao-He Zhu
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

Review 6.  Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.

Authors:  Claudia P Miller; Melissa M Singh; Nilsa Rivera-Del Valle; Christa A Manton; Joya Chandra
Journal:  J Biomed Biotechnol       Date:  2011-06-28

7.  Metabolic Profiling of a CB2 Agonist, AM9338, Using LC-MS and Microcoil-NMR: Identification of a Novel Dihydroxy Adamantyl Metabolite.

Authors:  Chandrashekhar Honrao; Xiaoyu Ma; Shashank Kulkarni; Vinit Joshi; Michael Malamas; Alexander Zvonok; JodiAnne Wood; David Strand; Jason J Guo; Alexandros Makriyannis
Journal:  Front Pharmacol       Date:  2020-09-30       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.